Genocea Biosciences (NASDAQ:GNCA) is scheduled to be announcing its earnings results before the market opens on Thursday, October 24th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, July 25th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.02). On average, analysts expect Genocea Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
GNCA opened at $2.60 on Tuesday. The business’s 50-day simple moving average is $3.07 and its 200-day simple moving average is $2.95. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.96 and a current ratio of 5.96. Genocea Biosciences has a one year low of $2.24 and a one year high of $11.28. The stock has a market capitalization of $68.25 million, a P/E ratio of -0.71 and a beta of 2.45.
A number of research firms have recently commented on GNCA. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, September 25th. HC Wainwright set a $32.00 target price on Genocea Biosciences and gave the stock a “buy” rating in a research report on Monday, September 30th. Stifel Nicolaus began coverage on Genocea Biosciences in a research report on Monday, July 8th. They set a “buy” rating on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Genocea Biosciences in a research report on Monday, September 30th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $17.50.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.